

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

### **VOLUNTARY ANNOUNCEMENT**

## **SUCCESSFULLY COMPLETION OF THE FIRST TWO IMPLANTS WITH THE Trilogy™ TRANSCATHETER HEART VALVE SYSTEM IN TAIWAN, CHINA**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce the successful completion of the first two implants for treating severe aortic regurgitation with the Trilogy™ Transcatheter Heart Valve (“**THV**”) System in Taiwan, China.

Trilogy™ THV System is a licensed-in CE-Mark approved transcatheter aortic valve replacement product. It is indicated for use in patients with symptomatic severe aortic regurgitation or symptomatic severe aortic stenosis who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET THE Trilogy™ THV SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, March 5, 2025

*As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. WaiMing YIP and Mr. Huacheng WEI as independent non-executive Directors.*